Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | (2) |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Estrella Immunopharma Inc | ESLAW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.11 | 08:33:22 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.11 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.11 | USD |
Estrella Immunopharma Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 4M | 36.38M | - | 0 | -7.31M | -0.20 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Estrella Immunopharma
| Date | Time | Source | Heading |
|---|---|---|---|
| 2/21/2025 | 07:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2/21/2025 | 07:30 | Business Wire | Estrella Immunopharma Completes First Dose Cohort in.. |
| 2/19/2025 | 15:46 | Business Wire | Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives.. |
| 2/14/2025 | 15:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2/14/2025 | 15:30 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 12/23/2024 | 13:43 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
| 12/19/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 12/17/2024 | 15:59 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/16/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 12/12/2024 | 16:08 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
| 12/09/2024 | 13:45 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
| 12/06/2024 | 08:12 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
ESLAW Historical
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE). |
NASDAQ:ESLAW -
What is the current Estrella Immunopharma Inc share price?
The current share price of Estrella Immunopharma Inc is US$ 0.11
How many Estrella Immunopharma Inc shares are in issue?
Estrella Immunopharma Inc has 36,376,000 shares in issue
What is the market cap of Estrella Immunopharma Inc?
The market capitalisation of Estrella Immunopharma Inc is USD 4M
What is the 1 year trading range for Estrella Immunopharma Inc share price?
Estrella Immunopharma Inc has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Estrella Immunopharma Inc?
The price to earnings ratio of Estrella Immunopharma Inc is -7.41
What is the reporting currency for Estrella Immunopharma Inc?
Estrella Immunopharma Inc reports financial results in USD
What is the latest annual profit for Estrella Immunopharma Inc?
The latest annual profit of Estrella Immunopharma Inc is USD -7.31M
What is the registered address of Estrella Immunopharma Inc?
The registered address for Estrella Immunopharma Inc is 108 W. 13TH STREET, SUITE 100, WILMINGTON, DELAWARE, 19801
Which industry sector does Estrella Immunopharma Inc operate in?
Estrella Immunopharma Inc operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector
